Creative Biolabs delivers end-to-end mRNA development services for genetic disease research, leveraging non-viral delivery platforms and sequence-engineering technologies to empower preclinical studies. Our solutions enable researchers to model pathogenesis, dissect molecular pathways, and explore corrective strategies—without genomic integration or viral interference.
Modular mRNA Design & Delivery
Next-Generation Delivery Platforms
Multi-Omics Validation Framework
Our integrated validation platform combines genomic stability analysis, transcriptional profiling, protein functional recovery, and cellular phenotyping.
Fig.1 Cross-Dimensional Efficacy Assessment for mRNA Engineering.
Target Identification
Precision Engineering
Validation & Data Delivery
Immunotherapy related mRNA Development
Protein Replacement Therapy-related mRNA Development
Regenerative Medicine-related mRNA Development
Therapeutic Antibody-coding mRNA Development
mRNA Pharmacology Optimization
Neuron-specific delivery of Cas9 RNP via engineered virus-like particles (RIDE system) achieves precise deletion of CAG repeats in the HTT gene, reducing mutant protein toxicity in Huntington's disease models. This approach demonstrates significantly lower off-target effects and inflammatory responses than viral vectors in non-human primate validation studies.
Multi-epitope mRNA vaccines integrate conserved regions of viral structural proteins, designed through immunoinformatic to cover >99% of HLA alleles. This strategy enables rapid development of research-grade vaccine prototypes for emerging pathogens, eliciting comprehensive B/T cell responses in preclinical models.
Liver-targeted mRNA delivery enables enzyme replacement therapy for phenylketonuria (PKU) research, demonstrating phenylalanine hydroxylase activity restoration in primary hepatocyte spheroids. Tissue-specific expression control minimizes systemic exposure while providing mechanistic insights into metabolic pathway recovery.
| Disease Area | Capabilities | Validation Models |
|---|---|---|
| Neurological Disorders |
In vivo delivery of neurotrophic factors to blood-brain barrier Huntington's disease modeling via CRISPR-corrected iPSC-derived neurons |
Humanized murine CNS models Cerebral organoids |
| Metabolic Diseases |
Liver-targeted mRNA for enzyme replacement Mitochondrial gene editing via TALEN mRNA co-delivery |
Primary hepatocyte spheroids Genetic knockout murine lines |
| Hematopathies |
RBC progenitor reprogramming for hemoglobinopathies Thrombosis models with anticoagulant protein mRNA |
Humanized bone marrow constructs Zebrafish genetic screens |
| Rare Genetic Syndromes |
Protein replacement for lysosomal storage disorders Exon-skipping mRNA for Duchenne muscular dystrophy |
Patient-derived fibroblast xenotransplants |
Creative Biolabs collaborates with research institutions to deploy mRNA solutions for:
Contact our team to design a project addressing:
Fig.2 mRNA Engineering Project Development.
Our platform utilizes ligand-guided nanoparticles designed for precise organ targeting, minimizing off-distribution while enabling disease-relevant pathway modulation in research models.
Key advantages include non-integrating expression preserving native genomics, tunable dosing for kinetic studies, and low immunogenicity critical for chronic disease modeling.
Blood-brain barrier-penetrating systems leverage receptor-specific targeting and microenvironment-responsive release mechanisms for neural applications.
Our virus-free editing platforms enable transient correction of disease mutations with enhanced specificity for mechanistic research.
Multi-dimensional assessment covers genomic integrity, functional recovery assays, and spatial transcriptomics, adhering to international research standards.
Reference
